Supernus Pharmaceuticals Completes Asset Acquisition
Ticker: SUPN · Form: 8-K · Filed: Jul 31, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, assets, pharmaceuticals
TL;DR
Supernus just bought some assets from Impel. Big moves ahead?
AI Summary
On July 30, 2025, Supernus Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from Impel Pharmaceuticals Inc. for an undisclosed amount. This filing also details other events and financial statements related to the company's operations.
Why It Matters
This acquisition could expand Supernus Pharmaceuticals' product portfolio and market reach, potentially leading to future revenue growth.
Risk Assessment
Risk Level: medium — The acquisition involves undisclosed financial terms and potential integration challenges, introducing a moderate level of risk.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- Impel Pharmaceuticals Inc. (company) — Seller of acquired assets
- July 30, 2025 (date) — Date of earliest event reported
FAQ
What specific assets were acquired from Impel Pharmaceuticals Inc.?
The filing states that Supernus Pharmaceuticals, Inc. completed the acquisition of 'certain assets' from Impel Pharmaceuticals Inc., but does not specify which assets.
What was the total purchase price for the acquired assets?
The filing does not disclose the specific dollar amount paid for the acquired assets from Impel Pharmaceuticals Inc.
When did the transaction for the asset acquisition occur?
The earliest event reported in this 8-K filing related to the acquisition occurred on July 30, 2025.
What is Supernus Pharmaceuticals, Inc.'s primary business?
Supernus Pharmaceuticals, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered at 9715 Key West Avenue, Rockville, MD 20850.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).